Vulvovaginal candidosis: contemporary challenges and the future of prophylactic and therapeutic approaches

Vulvovaginal candidosis (VVC) is a common gynaecological disorder that is delineated by the inflammation of vaginal wall and it is caused by the opportunistic fungal pathogen Candida species. In fact, three out of every four women will experience at least one occasion of VVC during some point in the...

Full description

Bibliographic Details
Main Authors: Shu, Yih Chew, Than, Leslie Thian Lung
Format: Article
Language:English
Published: Wiley-Blackwell Publishing 2016
Online Access:http://psasir.upm.edu.my/id/eprint/53242/
http://psasir.upm.edu.my/id/eprint/53242/1/Vulvovaginal%20candidosis%20contemporary%20challenges%20and%20the%20future%20of%20prophylactic%20and%20therapeutic%20approaches.pdf
_version_ 1848852232644067328
author Shu, Yih Chew
Than, Leslie Thian Lung
author_facet Shu, Yih Chew
Than, Leslie Thian Lung
author_sort Shu, Yih Chew
building UPM Institutional Repository
collection Online Access
description Vulvovaginal candidosis (VVC) is a common gynaecological disorder that is delineated by the inflammation of vaginal wall and it is caused by the opportunistic fungal pathogen Candida species. In fact, three out of every four women will experience at least one occasion of VVC during some point in their lives. Although uncomplicated VVC is relatively harmless, the complicated VVC such as recurrent attack often creates restlessness and depression in the patients, thus greatly affects their quality of life. Managements of VVC are usually associated with the use of antimycotic suppositories, topical cream or oral agents. These antimycotic agents are either available over-the-counter or prescribed by the clinicians. In recent decades, the rise of clinical challenges such as the increased prevalence of resistant Candida strains, recurrent VVC infection and adverse effects of multidrug interactions have necessitated the development of novel therapeutic or prophylactic options to combat the complicated VVC in the future. In this review, we discuss the current antimycotic treatments available for Candida vaginitis and the problems that exist in these seemingly effective treatments. Besides, we attempt to contemplate some of the future and prospective strategies surrounding the development of alternative therapeutic and prophylactic options in treating and preventing complicated VVC respectively.
first_indexed 2025-11-15T10:34:49Z
format Article
id upm-53242
institution Universiti Putra Malaysia
institution_category Local University
language English
last_indexed 2025-11-15T10:34:49Z
publishDate 2016
publisher Wiley-Blackwell Publishing
recordtype eprints
repository_type Digital Repository
spelling upm-532422017-09-29T03:50:15Z http://psasir.upm.edu.my/id/eprint/53242/ Vulvovaginal candidosis: contemporary challenges and the future of prophylactic and therapeutic approaches Shu, Yih Chew Than, Leslie Thian Lung Vulvovaginal candidosis (VVC) is a common gynaecological disorder that is delineated by the inflammation of vaginal wall and it is caused by the opportunistic fungal pathogen Candida species. In fact, three out of every four women will experience at least one occasion of VVC during some point in their lives. Although uncomplicated VVC is relatively harmless, the complicated VVC such as recurrent attack often creates restlessness and depression in the patients, thus greatly affects their quality of life. Managements of VVC are usually associated with the use of antimycotic suppositories, topical cream or oral agents. These antimycotic agents are either available over-the-counter or prescribed by the clinicians. In recent decades, the rise of clinical challenges such as the increased prevalence of resistant Candida strains, recurrent VVC infection and adverse effects of multidrug interactions have necessitated the development of novel therapeutic or prophylactic options to combat the complicated VVC in the future. In this review, we discuss the current antimycotic treatments available for Candida vaginitis and the problems that exist in these seemingly effective treatments. Besides, we attempt to contemplate some of the future and prospective strategies surrounding the development of alternative therapeutic and prophylactic options in treating and preventing complicated VVC respectively. Wiley-Blackwell Publishing 2016 Article PeerReviewed application/pdf en http://psasir.upm.edu.my/id/eprint/53242/1/Vulvovaginal%20candidosis%20contemporary%20challenges%20and%20the%20future%20of%20prophylactic%20and%20therapeutic%20approaches.pdf Shu, Yih Chew and Than, Leslie Thian Lung (2016) Vulvovaginal candidosis: contemporary challenges and the future of prophylactic and therapeutic approaches. Mycoses, 59 (5). pp. 262-273. ISSN 0933-7407; ESSN: 1439-0507 http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1439-0507
spellingShingle Shu, Yih Chew
Than, Leslie Thian Lung
Vulvovaginal candidosis: contemporary challenges and the future of prophylactic and therapeutic approaches
title Vulvovaginal candidosis: contemporary challenges and the future of prophylactic and therapeutic approaches
title_full Vulvovaginal candidosis: contemporary challenges and the future of prophylactic and therapeutic approaches
title_fullStr Vulvovaginal candidosis: contemporary challenges and the future of prophylactic and therapeutic approaches
title_full_unstemmed Vulvovaginal candidosis: contemporary challenges and the future of prophylactic and therapeutic approaches
title_short Vulvovaginal candidosis: contemporary challenges and the future of prophylactic and therapeutic approaches
title_sort vulvovaginal candidosis: contemporary challenges and the future of prophylactic and therapeutic approaches
url http://psasir.upm.edu.my/id/eprint/53242/
http://psasir.upm.edu.my/id/eprint/53242/
http://psasir.upm.edu.my/id/eprint/53242/1/Vulvovaginal%20candidosis%20contemporary%20challenges%20and%20the%20future%20of%20prophylactic%20and%20therapeutic%20approaches.pdf